Minerva Neurosciences, Inc.
NERV
$7.85
$0.010.13%
NASDAQ
Rating
Reward
Risk
Rating Factors
Growth Index
Efficiency Index
Solvency Index
Total Return Index
Volatility Index
Dividend Yield Index
Headlines
3/17/2026
-
Tickeron - Technical Analysis
3/16/2026
-
TipRanks Financial Blog
3/16/2026
-
MarketBeat
3/13/2026
-
MarketBeat
3/12/2026
-
Globe Newswire
3/12/2026
-
Tickeron - Technical Analysis
3/12/2026
-
TipRanks Financial Blog
3/11/2026
-
Ticker Report
3/11/2026
-
MarketBeat
3/11/2026
-
SeekingAlpha.com: All News
3/11/2026
-
Seeking Alpha - Healthcare
3/11/2026
-
Globe Newswire
Minerva Neurosciences (NERV, $8.05) price may drop as it broke higher Bollinger Band on Mar 09, 2026
3/10/2026
-
Tickeron - Stocks
3/10/2026
-
Tickeron - Stocks
3/10/2026
-
Tickeron - Stocks
3/6/2026
-
Tickeron - Stocks
3/6/2026
-
Tickeron - Stocks
3/6/2026
-
Tickeron - Stocks
3/4/2026
-
Globe Newswire
3/3/2026
-
Tickeron - Stocks
2/28/2026
-
Tickeron - Technical Analysis
2/28/2026
-
Tickeron - Technical Analysis
2/28/2026
-
MarketBeat
2/26/2026
-
Tickeron - Stocks
Income Statement
Total Revenue (TTM)
--
EBITDA (TTM)
EBIT (TTM)
Net Income (TTM)
Balance Sheet
Total Assets (Q)
Total Debt (Q)
Total Liabilities (Q)
Book Value Per Share (Q)
Cash Flow
Cash from Operations (TTM)
Cash from Investing (TTM)
--
Cash from Financing (TTM)
Net Change in Cash (TTM)
Filings
Filing Date
Wednesday, November 5, 2025
Period Date
Tuesday, September 30, 2025
Next Filing
Week of Feb 23 and 27 (est)
Price History
Beta
7-Day Total Return
30-Day Total Return
60-Day Total Return
90-Day Total Return
Year to Date Total Return
1-Year Total Return
2-Year Total Return
3-Year Total Return
5-Year Total Return
52-week Low
52-week High
Valuation
Enterprise Value
Price/Sales (TTM)
--
Price/Book (Q)
Dividends and Shares
Shares Outstanding
Dividend Per Share (Most Recent)
--
Dividend Per Share (TTM)
--
Corporate Info
Website
Phone Number
617 600 7373
Address
1500 District Avenue
Burlington, MA 01803
Burlington, MA 01803
Country
Year Founded
Business Description
Sector
Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system...
more